The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne’s Muscular Dystrophy
Open accessAbstract
We treated a 27-year-old patient with Duchenne’s muscular dystrophy (DMD) with recombinant adeno-associated virus (rAAV) serotype 9 containing dSaCas9 (i.e., “dead” Staphylococcus aureus Cas9, in which the Cas9 nuclease activity has been inactivated) fused to VP64; this transgene was designed to up-regulate cortical dystrophin as a custom CRISPR–transactivator therapy. The dose of rAAV used was 1×1014 vector genomes per kilogram of body weight. Mild cardiac dysfunction and pericardial effusion developed, followed by acute respiratory distress syndrome (ARDS) and cardiac arrest 6 days after transgene treatment; the patient died 2 days later. A postmortem examination showed severe diffuse alveolar damage. Expression of transgene in the liver was minimal, and there was no evidence of AAV serotype 9 antibodies or effector T-cell reactivity in the organs. These findings indicate that an innate immune reaction caused ARDS in a patient with advanced DMD treated with high-dose rAAV gene therapy. (Funded by Cure Rare Disease.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although AAV is substantially less inflammatory compared with many other viral vectors, treatments may require administration of high vector doses of up to 10 14 vg/ kg, in particular for applications that depend on systemic vector administration.”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012) · Science · doi:10.1126/science.1225829 · Cited by 17,116
Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression
Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., & Lim, W. A. (2013) · Cell · doi:10.1016/j.cell.2013.02.022 · Cited by 5,016
Mali, P., Aach, J., Stranges, P. B., Esvelt, K. M., Moosburner, M., Kosuri, S., Yang, L., & Church, G. M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2675 · Cited by 1,752
Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Duan, D., Goemans, N., Takeda, S., Mercuri, E. M., & Aartsma-Rus, A. M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00248-3 · Cited by 1,345
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175
Effect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029
The Dystrophin Glycoprotein Complex
Lapidos, K. A., Kakkar, R. K., & McNally, E. M. (2004) · Circulation Research · doi:10.1161/01.res.0000126574.61061.25 · Cited by 534
The Dystrophin Complex: Structure, Function, and Implications for Therapy
Gao, Q. Q., & McNally, E. M. (2015) · Comprehensive physiology · doi:10.1002/cphy.c140048 · Cited by 521
Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
Duan, D. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.011 · Cited by 489
Dystrophin-Deficient Cardiomyopathy
Kamdar, F. D., & Garry, D. J. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.02.081 · Cited by 392
Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing
Chemello, F., Chai, A. C., Li, H. Z., Rodríguez-Caycedo, C., Sanchez‐Ortiz, E., Atmanli, A., Mireault, A. A., Liu, N., Bassel‐Duby, R., & Olson, E. N. (2021) · Science Advances · doi:10.1126/sciadv.abg4910 · Cited by 255
Gene Therapy for Duchenne Muscular Dystrophy
Elangkovan, N., & Dickson, G. (2021) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-210678 · Cited by 215
Correlation of Scoliosis and Pulmonary Function in Duchenne Muscular Dystrophy
Kurz, L. T., Mubarak, S. J., Schultz, P., Park, S., & Leach, J. (1983) · Journal of Pediatric Orthopaedics · doi:10.1097/01241398-198307000-00014 · Cited by 149
The role of the dystrophin glycoprotein complex in muscle cell mechanotransduction
Wilson, D. G. S., Tinker, A., & Iskratsch, T. (2022) · Communications Biology · doi:10.1038/s42003-022-03980-y · Cited by 125
X-linked dilated cardiomyopathy and the dystrophin gene
Ferlini, A., Sewry, C. A., Melis, M. A., Mateddu, A., & Francesco Muntoni, A. (1999) · Neuromuscular Disorders · doi:10.1016/s0960-8966(99)00015-2 · Cited by 118
Micro-Dystrophin Gene Therapy Goes Systemic in Duchenne Muscular Dystrophy Patients
Duan, D. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.012 · Cited by 102
Zhang, Y., & Duan, D. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.131 · Cited by 95
Multiple pathogenetic mechanisms in X linked dilated cardiomyopathy
Cohen, N., & Francesco Muntoni, A. (2004) · Heart · doi:10.1136/hrt.2003.023390 · Cited by 78
Manini, A., Abati, E., Nuredini, A., Corti, S. P., & Comi, G. P. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.814174 · Cited by 76
Lek, A., Atas, E., Hesterlee, S. E., Byrne, B. J., & Bönnemann, C. G. (2023) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-221639 · Cited by 62
Self-citationKwon, J. B., Ettyreddy, A. R., Vankara, A., Bohning, J. D., Devlin, G. W., Hauschka, S. D., Asokan, A., & Gersbach, C. A. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.09.016 · Cited by 60
Mbakam, C. H., Rousseau, J., Tremblay, G., Yaméogo, P., & Tremblay, J. P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116160 · Cited by 36
Micro-dystrophin Genes Bring Hope of an Effective Therapy for Duchenne Muscular Dystrophy
Davies, K. E., & Guiraud, S. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.019 · Cited by 29
Immune Responses to Muscle-Directed Adeno-Associated Viral Gene Transfer in Clinical Studies
Kumar, S. R. P., Duan, D., & Herzog, R. W. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.056 · Cited by 28
Lek, A., Ma, K., Woodman, K. G., & Lek, M. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.241 · Cited by 2
Self-citation
Cited by
Sorted by citations
Adeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
Self-citationCRISPR technologies for genome, epigenome and transcriptome editing
Villiger, L., Joung, J., Koblan, L. W., Weissman, J. S., Abudayyeh, O. O., & Gootenberg, J. S. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00697-6 · Cited by 280
Lethal immunotoxicity in high-dose systemic AAV therapy
Duan, D. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.10.015 · Cited by 240
Lian, X., Chatterjee, S., Sun, Y., Dilliard, S. A., Moore, S., Xiao, Y., Bian, X., Yamada, K., Sung, Y., Levine, R. M., et al. (2024) · Nature Nanotechnology · doi:10.1038/s41565-024-01680-8 · Cited by 140
Current clinical applications of AAV-mediated gene therapy
Byrne, B. J., Flanigan, K. M., Matesanz, S. E., Finkel, R. S., Waldrop, M. A., D'Ambrosio, E. S., Johnson, N. E., Smith, B. K., Bönnemann, C. G., Carrig, S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.045 · Cited by 152
Metadata
- Authors
- Lek, A., Wong, B., Keeler, A., Blackwood, M., Ma, K., Huang, S., Sylvia, K., Batista, A. R., Artinian, R., Kokoski, D., Parajuli, S., Putra, J., Carreon, C. K., Lidov, H., Woodman, K., Pajusalu, S., Spinazzola, J. M., Gallagher, T., LaRovere, J., Balderson, D., Black, L., Sutton, K., Horgan, R., Lek, M., & Flotte, T.
- Affiliations
- Yale University (US)
- University of Massachusetts Chan Medical School (US)
- Boston Children's Hospital (US)
- Tartu University Hospital (EE)
- Wake Technical Community College (US)
- Charles River Laboratories (United States) (US)
- Cure Rare Disease, Woodbridge, CT, USA.
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-09-28
- Volume
- 389
- Issue
- 13
- Pages
- 1203-1210
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC11288170
- OpenAlex
- W4387077861
- Cited by
- 319
- References
- 26
- Citations by year
- 2026: 80 · 2025: 125 · 2024: 97 · 2023: 17
- FWCI
- 52.96
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (P01HL158506)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- Duchenne muscular dystrophy, gene therapy toxicity, acute respiratory distress syndrome, cardiac arrest, diffuse alveolar damage, innate immune response, autopsy
- MeSH terms
- Adult, Antibodies, Humans, Immunity, Innate, Respiratory Distress Syndrome, Genetic Therapy, Dystrophin, Fatal Outcome, Transgenes, Muscular Dystrophy, Duchenne
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
